Adição na publicação
#15.35
10/19/2021
RPI 2650
Application data
Number
112019021125Type
Filing
Publication
PCT
US2018026699 The application was abandoned: examination was not requested within the 36 months following the 04/09/2018 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.
Talk to a specialistLatest action published by the INPI: 10/19/2021. We update with every new RPI gazette, published weekly.
Applicants
C. C. (pessoa física)
US
Inventors
K. C. (pessoa física)
US
T. C. (pessoa física)
US
IPC Classification
Priority claims
US
62/483,555 · 04/10/2017
Abstract
A presente invenção refere-se ao uso de um antagonista de NK1 em combinação com 6-propilamino-4,5,6,7-tetra-hidro-1,3-benzotiazol-2-amina, para facilitar o tratamento de um paciente sofrendo de uma sinucleinopatia permitindo que uma dose diária terapeuticamente eficaz de 6-propilamino-4,5,6,7-tetra-hidro-1,3-benzotiazol-2-amina aja sem os efeitos adversos típicos causados pelo mono-hidrato de dicloridrato de pramipexol quando administrado sozinho.
Publications in the Brazilian Industrial Property Gazette (RPI).
#15.35
10/19/2021
RPI 2650
#11.1.1
10/05/2021
RPI 2648
#11.1
07/20/2021
RPI 2637
#1.3
05/12/2020
RPI 2575
#1.1
10/15/2019
RPI 2545
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.